Bridging allogeneic origin and personalized tumor targeting
Immunicum’s lead development candidate ilixadencel (formerly known as INTUVAX®) uses dendritic cells harvested from healthy human donors that are specifically activated to produce significant amounts of vigorous immune stimulatory factors. By administration through intratumoral injection, these cells induce a local inflammatory reaction, leading to a local destruction of tumor cells and recruitment of the patient’s own dendritic cells into the tumor environment. The recruited dendritic cells will encounter and engulf dying tumor cells and/or tumor cell debris, including the full array of tumor specific proteins, called neoantigens, that will act as an antigen source to activate and alert the tumor specific T cells, including cytotoxic T cells, resulting in a highly personalized anti-tumor response.
Ilixadencel is currently being evaluated in clinical trials for a range of solid tumors including renal cell carcinoma, hepatic cell carcinoma and gastrointestinal stromal carcinoma.